Pulmonx CEO sells 41,882 shares at $2.26

Pulmonx’s CEO reported tax-withholding-related sales totaling 41,882 shares and an indirect family-trust holding of 918,198 shares of common stock.

Rhea-AI Filing Summary

Pulmonx Corp (LUNG) reported that President and CEO, and director, Glendon E. French III sold a total of 41,882 shares of common stock on September 1, 2026 at $2.26 per share in transactions described as sales to cover tax withholding obligations arising from the vesting of Restricted Stock Units granted on March 1, 2023 and December 1, 2025. A footnote also notes the acquisition of 1,656 shares under Pulmonx’s 2020 Employee Stock Purchase Plan on August 14, 2026, and French is reported as indirectly holding 918,198 shares of common stock through a family trust for which he and his spouse serve as trustees and beneficiaries. No Rule 10b5-1 trading plan is reported for these transactions.

Insider Trade Summary

Net Seller: 41,882 shares

Net Sell 3 txns

Insider French Glendon E. III

Role President and CEO

Sold 41,882 shs ($95K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	4,098	$2.26	$9K
Sale	Common Stock F3	37,784	$2.26	$85K
holding	Common Stock F4	--	--	--

Holdings After Transaction: Common Stock — 1,137,936 shares (Direct); Common Stock — 918,198 shares (Indirect, By trust)

Footnotes (4)

1. F1. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2023.
2. F2. Includes 1,656 shares acquired by the reporting person under the Issuer's 2020 Employee Stock Purchase Plan on August 14, 2026.
3. F3. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on December 1, 2025.
4. F4. The shares are held by the Glendon E French & Gayle French Trustees French Family Rev Trust UA DTD 08/29/2012, of which the reporting person and his spouse are trustees and beneficiaries.

Key Figures

Shares sold (first transaction): 4,098 shares Shares sold (second transaction): 37,784 shares Total shares sold: 41,882 shares +3 more

6 metrics

Shares sold (first transaction) 4,098 shares Common stock sold on September 1, 2026 to cover tax withholding on RSUs granted March 1, 2023

Shares sold (second transaction) 37,784 shares Common stock sold on September 1, 2026 to cover tax withholding on RSUs granted December 1, 2025

Total shares sold 41,882 shares Aggregate of the two reported common stock sales on September 1, 2026

Sale price per share $2.26 per share Price for both reported common stock sales on September 1, 2026

Indirect holdings by family trust 918,198 shares Common stock held indirectly by the French family trust after the reported transactions

Shares acquired under ESPP 1,656 shares Common stock acquired under the 2020 Employee Stock Purchase Plan on August 14, 2026

Key Terms

Restricted Stock Units (the "RSUs"), tax withholding obligations, 2020 Employee Stock Purchase Plan, trustees and beneficiaries

4 terms

Restricted Stock Units (the "RSUs") financial

"in connection with the vesting of the Restricted Stock Units (the "RSUs") granted"

tax withholding obligations financial

"shares were sold by the reporting person to cover tax withholding obligations in"

2020 Employee Stock Purchase Plan financial

"acquired by the reporting person under the Issuer's 2020 Employee Stock Purchase Plan"

trustees and beneficiaries financial

"of which the reporting person and his spouse are trustees and beneficiaries"

FAQ

What insider transactions did Pulmonx (LUNG) report for CEO Glendon E. French III?

Pulmonx reported that Glendon E. French III sold 41,882 shares of common stock on September 1, 2026 at $2.26 per share. The transactions are described as sales to cover tax withholding obligations related to the vesting of previously granted RSUs.

At what price were the Pulmonx (LUNG) shares sold in this Form 4 filing?

The filing states that the CEO’s reported sales of Pulmonx common stock on September 1, 2026 were executed at $2.26 per share. This price applies to both the 4,098-share sale and the separate 37,784-share sale reported.

Were the Pulmonx (LUNG) insider sales discretionary or for tax withholding?

The filing states the 4,098-share and 37,784-share sales were made to cover tax withholding obligations arising from the vesting of RSUs granted on March 1, 2023 and December 1, 2025, respectively.

How many Pulmonx (LUNG) shares does the CEO hold indirectly after these transactions?

The Form 4 reports that 918,198 shares of Pulmonx common stock are held indirectly by a family trust, for which Glendon E. French III and his spouse serve as trustees and beneficiaries.

Did the Pulmonx (LUNG) CEO acquire any shares near the time of these reported sales?

Yes. A footnote explains that the CEO acquired 1,656 shares of Pulmonx common stock under the company’s 2020 Employee Stock Purchase Plan on August 14, 2026, which are included in the post-transaction share amount referenced for one of the sales.

Were the Pulmonx (LUNG) insider transactions under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is not selected, indicating that these reported transactions were not affirmed as being made under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 06:26 PM Accepted by SEC EDGAR 09/03/2026 - 06:23 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

French Glendon E. III

(Last) (First) (Middle)

C/O PULMONX CORPORATION

700 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pulmonx Corp [ LUNG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/01/2026		S(1)		4,098	D	$2.26	1,175,720(2)	D
Common Stock	09/01/2026		S(3)		37,784	D	$2.26	1,137,936	D
Common Stock								918,198	I	By trust(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2023.

2. Includes 1,656 shares acquired by the reporting person under the Issuer's 2020 Employee Stock Purchase Plan on August 14, 2026.

3. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on December 1, 2025.

4. The shares are held by the Glendon E French & Gayle French Trustees French Family Rev Trust UA DTD 08/29/2012, of which the reporting person and his spouse are trustees and beneficiaries.

	/s/ David Aaron Lehman, Attorney-in-Fact	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)